Agile therapeutics inc (AGRX)
CashFlow / Yearly
Dec'19Dec'18Dec'17Dec'16Dec'15Dec'14Dec'13Dec'12
Cash flows from operating activities:
Net loss

-18,606

-19,779

-28,304

-28,741

-30,335

-

-

-

Net loss

-

-

-

-

-

-16,077

-14,321

-

Net loss (income)

-

-

-

-

-

-

-

-23,260

Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation

18

23

23

19

18

12

12

23

Amortization

145

-

-

-

-

-

-

-

Noncash stock bonus

-

-

-

-

-

80

80

-

Noncash stock bonus

-

-

-

-

-

-

80

-

Noncash stock based compensation

1,762

3,630

3,651

3,425

2,965

1,381

1,338

665

Loss on extinguishment of debt

-

-

-

-

-1,036

-

-

-

Noncash interest

-

282

667

946

590

185

133

83

Change in fair value of warrants

-

-29

-143

-234

110

-348

81

-171

Changes in operating assets and liabilities:
Prepaid expenses and other assets

233

-155

-2,006

-922

1,209

2,335

-107

33

Accounts payable and accrued expenses

1,377

-1,177

-2,460

362

1,347

2,599

-449

-275

Lease liability

152

-

-

-

-

-

-

-

Net cash used in operating activities

-15,689

-16,895

-24,560

-23,301

-25,478

-

-

-

Cash flows from investing activities:
Net cash used in operating activities

-

-

-

-

-

-14,503

-13,019

-22,967

Acquisition of property and equipment

98

318

1,313

31

290

96

4,945

6,692

Net cash used in investing activities

-98

-318

-1,313

-31

-290

-

-

-

Cash flows from financing activities:
Proceeds from issuance of preferred stock, net of offering costs

-

-

-

-

-

-

-

19,315

Proceeds from issuance of common stock, in public offering, net of offering costs

-

-

-

-

-

49,744

-

-

Proceeds from issuance of common stock in private placement, net of offering costs

-

-

-

-

19,330

-

-

-

Return of principal payments of long-term debt

-

-

-

985

-

-

-

-

Proceeds from sales or issuance of common stock, net of offering costs

-

-

-

37,528

-

-

-

-

Proceeds from issuance of long-term debt

-

-

-

-

-

-

-

15,000

Net cash used in investing activities

-

-

-

-

-

-96

-4,945

-6,692

Proceeds from convertible bridge notes

-

-

-

-

-

3,000

-

6,000

Proceeds from issuance term loan

-

-

-

-

16,265

-

-

-

Repayment of term loan

-

-

-

-

15,784

-

-

-

Principal payments of long-term debt

-

10,888

5,612

985

-

-

-

-

Debt financing costs paid

-

-

-

175

423

150

-

202

Proceeds from exercise of stock options

164

-

152

334

593

67

70

-

Net cash provided by financing activities

42,415

-10,888

13,075

37,687

19,981

-

-

-

Net increase in cash and cash equivalents

26,628

-28,101

-12,798

14,355

-

-

-

-

Interest paid

-

-

-

-

-

1,380

1,380

56

Supplemental disclosure of noncash financing activities
Net (decrease) increase in cash and cash equivalents

-

-

-

-

-5,787

-

-

-

Net cash provided by (used in) financing activities

-

-

-

-

-

52,661

70

40,112

Net increase (decrease) in cash and cash equivalents

-

-

-

-

-

38,062

-17,894

10,451

Supplemental cash flow information
Interest paid

-

1,370

1,295

1,500

1,474

-

-

-

Fair value of common stock warrants issued

-

-

-

-

1,184

-

-

-

Property and equipment purchases included in accounts payable

49

-

242

-

-

-

-

-

Conversion of preferred stock into common stock

-

-

-

-

-

69,233

-

-

Conversion of notes payable and interest into common stock

-

-

-

-

-

3,021

-

-

At-the-market sales
Proceeds from sales or issuance of common stock, net of offering costs

42,251

-

18,535

-

-

-

-

-